Aerobic exercise improves insulin resistance and decreases body fat and serum levels of leptin in patients with hepatitis C virus

Hepatology Research

Volumn 41, Issue 10, 2011, Pages 928-935

  Konishi, Ichiro ^a   Hiasa, Yoichi ^a   Tokumoto, Yoshio ^a   Abe, Masanori ^a   Furukawa, Shinya ^a   Toshimitsu, Kumiko ^b   Matsuura, Bunzo ^a   Onji, Morikazu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b EHIME UNIVERSITY HOSPITAL   (Japan)

Author keywords

Adiponectin; Hepatocellular carcinoma; Tumor necrosis factor ; Visceral fat; Walking

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; INTERLEUKIN 6; LEPTIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AEROBIC EXERCISE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; DIET THERAPY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIVER FUNCTION TEST; MALE; MUSCLE MASS; NUTRITION; PEDOMETER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SHORT FORM 36; SUBCUTANEOUS FAT; WALKING;

EID: 80053238945     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00833.x     Document Type: Article

References (39)

1. Ikeda K, Saitoh S, Suzuki Y etal. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930-8.
2. Niederau C, Lange S, Heintges T etal. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-95.
3. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228-33.
4. Caronia S, Taylor K, Pagliaro L etal. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30: 1059-63.
5. Mason AL, Lau JY, Hoang N etal. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328-33.
6. Shintani Y, Fujie H, Miyoshi H etal. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-8.
7. Delgado-Borrego A, Jordan SH, Negre B etal. Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol 2010; 8: 458-62.
8. Muzzi A, Leandro G, Rubbia-Brandt L etal. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005; 42: 41-6.
9. Romero-Gomez M, Del Mar Viloria M, Andrade RJ etal. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.
10. Lo Iacono O, Venezia G, Petta S etal. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007; 25: 1181-91.
11. Gastaldelli A, Miyazaki Y, Mahankali A etal. The effect of pioglitazone on the liver: role of adiponectin. Diabetes Care 2006; 29: 2275-81.
12. Nishitani S, Matsumura T, Fujitani S, Sonaka I, Miura Y, Yagasaki K. Leucine promotes glucose uptake in skeletal muscles of rats. Biochem Biophys Res Commun 2002; 299: 693-6.
13. Nishitani S, Takehana K, Fujitani S, Sonaka I. Branched-chain amino acids improve glucose metabolism in rats with liver cirrhosis. Am J Physiol Gastrointest Liver Physiol 2005; 288: 1292-300.
14. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-70.
15. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947-53.
16. Arita Y, Kihara S, Ouchi N etal. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
17. Cua IH, Hui JM, Bandara P etal. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 2007; 46: 66-73.
18. Havel PJ, Kasim-Karakas S, Mueller W, Johnson PR, Gingerich RL, Stern JS. Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab 1996; 81: 4406-13.
19. Solomon TP, Sistrun SN, Krishnan RK etal. Exercise and diet enhance fat oxidation and reduce insulin resistance in older obese adults. J Appl Physiol 2008; 104: 1313-19.
20. Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis. Diabetes Care 2006; 29: 2518-27.
21. Courneya KS, Sellar CM, Stevinson C etal. Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients. J Clin Oncol 2009; 27: 4605-12.
22. Courneya KS, Mackey JR, Bell GJ, Jones LW, Field CJ, Fairey AS. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol 2003; 21: 1660-8.
23. Ritland S, Foss NE, Gjone E. Physical activity in liver disease and liver function in sportsmen. Scand J Soc Med Suppl 1982; 29: 221-6.
24. Bonora E, Formentini G, Calcaterra F etal. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002; 25: 1135-41.
25. Fukuhara SSY, Bito S, Kurokawa K. Manual of SF-36, Japanese Version 1.2. Tokyo: Public Health Research Foundation, 2001.
26. Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002; 51: 3391-9.
27. Senn JJ, Klover PJ, Nowak IA etal. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 2003; 278: 13740-6.
28. Gielen S, Adams V, Mobius-Winkler S etal. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol 2003; 42: 861-8.
29. Romero-Gomez M, Castellano-Megias VM, Grande L etal. Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. Am J Gastroenterol 2003; 98: 1135-41.
30. Brabant G, Muller G, Horn R, Anderwald C, Roden M, Nave H. Hepatic leptin signaling in obesity. FASEB J 2005; 19: 1048-50.
31. Ribatti D, Belloni AS, Nico B, Di Comite M, Crivellato E, Vacca A. Leptin-leptin receptor are involved in angiogenesis in human hepatocellular carcinoma. Peptides 2008; 29: 1596-602.
32. Saxena NK, Sharma D, Ding X etal. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 2007; 67: 2497-507.
33. Ikejima K, Takei Y, Honda H etal. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002; 122: 1399-410.
34. Yang WS, Lee WJ, Funahashi T etal. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815-19.
35. Hulver MW, Zheng D, Tanner CJ etal. Adiponectin is not altered with exercise training despite enhanced insulin action. Am J Physiol Endocrinol Metab 2002; 283: 861-5.
36. Garcia-Pagan JC, Santos C, Barbera JA etal. Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension. Gastroenterology 1996; 111: 1300-6.
37. Konishi I, Hiasa Y, Shigematsu S etal. Diabetes pattern on the 75g oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus. Liver Int 2009; 29: 1194-201.
38. Veldt BJ, Chen W, Heathcote EJ etal. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008; 47: 1856-62.
39. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-44.